DNA-based alphaviral RNA replicon vectors, also called suicidal DNA vectors, alleviate the concerns of integration or transformation related to conventional DNA vectors since suicidal DNA vectors eventually cause apoptosis of transfected cells. However, the expression of inserted genes in these vectors is transient and the potency of suicidal DNA vaccines may be compromised because of apoptotic cell death. Therefore, to enhance the immune response to the human papillomavirus type 16 (HPV-16) E7 antigen, we generated a DNA-based Semliki Forest virus vector, pSCA1, encoding E7 fused with BCL-xL, an antiapoptotic member of the BCL-2 family. Our results indicated that pSCA1 encoding E7/BCL-xL fusion protein delayed cell death in the pSCA1-transfected dendritic cell line and generated significantly higher E7-specific CD8 þ T-cell-mediated immune responses and better antitumor effects than pSCA1 encoding wild-type E7 gene in vaccinated mice. The antiapoptotic function of BCL-xL is important for the enhancement of antigen-specific CD8 þ T-cell responses in vaccinated mice, because a point mutant of BCL-xL lacking antiapoptotic function was ineffective. These results suggest that strategies to delay suicidal DNA-induced cell death using antiapoptotic proteins may greatly enhance the potency of suicidal DNA.
Introduction
Nucleic acid vaccines have emerged as a promising approach to vaccine development. 1, 2 The use of naked DNA for vaccination has the advantages of purity, simplicity of preparation, and stability. Furthermore, multiple DNA vaccines can be administered simultaneously and repeatedly. Intradermal administration of DNA vaccines via gene gun can be used to deliver efficiently genes of interest into professional antigen presenting cells (APCs) in vivo. 3 The skin contains numerous bone marrow-derived APCs (called Langerhans cells) that are able to move through the lymphatic system from the site of injection to draining lymph nodes, where they prime antigen-specific T cells. 4 The use of conventional naked DNA vaccines, nonetheless, does raise certain concerns, such as potential integration into the host genome and cell transformation. DNA-based alphaviral RNA replicon vectors, also called suicidal DNA vectors, have been employed as an important strategy to alleviate the concerns for potential chromosomal integration and cell transformation generated by the use of naked DNA vaccines because these vectors eventually cause apoptotic cell death of transfected cells. 5, 6 This feature is particularly desirable for vaccine development targeting potentially oncogenic proteins, such as the human papillomavirus type 16 (HPV-16) E7 protein. We have previously used the Semliki Forest virus-derived suicidal DNA vector, pSCA1, for our HPV DNA vaccine development. 7 While the induction of programmed cell death by suicidal DNA vectors can be advantageous in preventing cell transformation, it can shorten the useful lifespan of dendritic cells (DCs) if DNA is targeted to DCs, thereby reducing their effectiveness in stimulating the immune system. Thus, the expression of inserted genes in these vectors may be short and the potency of suicidal DNA vaccines may be compromised. In our previous studies, we found that vaccination with pSCA1 suicidal DNA vectors encoding Mycobacterium tuberculosis heat shock protein 70 (HSP70) linked to a model antigen, HPV-16 E7, generated significantly weaker E7-specific CD8 þ T cells 7 compared to vaccination with a conventional DNA vector (pcDNA3) encoding the same E7/HSP70 gene (pcDNA3-E7/HSP70) when DNA was administered intradermally via gene gun. 7, 8 A potential explanation for the observed difference may be that the pSCA1 vector causes apoptosis of transfected cells. Since we used a gene gun to deliver these DNA vaccines directly to professional APCs within skin, cell death induced by the pSCA1 vector may thus limit the lifespan and ability of the APCs to present directly the E7 antigen to T cells. We reasoned that a strategy capable of delaying suicidal DNA-induced apoptotic cell death may enhance the priming of antigen-specific T-cell-mediated immune responses and generate strong antitumor effects against antigen-expressing tumors when suicidal DNA is administered intradermally via gene gun.
We evaluated the effect of linking BCL-xL, a member of the BCL-2 antiapoptotic protein family, to HPV-16 E7 in the context of E7-specific CD8 þ T-cell-mediated immune responses and antitumor effects against an E7-expressing tumor model generated by the pSCA1 suicidal DNA vector. Our results indicated that BCL-xL delayed cell death of transfected DCs and generated significantly higher E7-specific CD8 þ T-cell-mediated immune responses and better antitumor effects than pSCA1 DNA containing E7 gene alone in vaccinated mice. Furthermore, we confirmed that the antiapoptotic function of BCL-xL is important for the enhancement of antigen-specific CD8 þ T-cell responses in vaccinated mice using a mutant BCL-xL (mt 7), 9 which has point mutations in a region critical to antiapoptotic function (aa 135-137 in the BH1 domain). Thus, the employment of antiapoptotic strategies with suicidal DNA vaccine not only provides better safety features but also generates comparable potency to conventional DNA vaccines. This newly developed suicidal DNA vaccine strategy has potential clinical implications.
Results
The suicidal DNA vector containing BCL-xL gene reduces suicidal DNA-induced cell death
We have characterized and compared the pSCA1 plasmid-driven expression of E7/BCL-xL and E7/mt BCL-xL proteins using Western blot analysis and noted that the expression levels of wild-type and mutant forms of the proteins are equivalent (data not shown).
To examine whether the linkage of BCL-xL gene to antigenic gene in suicidal DNA vector can reduce suicidal DNA-induced cell death, we measured cell death of the various pSCA1 DNA-transfected cells using propidium iodide (PI). The DC variant (DC-V) cell line was selected as a model to investigate the survival of the DCs after transfecting these cells with various suicidal DNA construct. Although there are differences between using a DC line and murine bone marrow-derived DC, these immortalized clones display dendritic morphology, and many express the DC-specific markers DEC-205 and 33D1 as well as high levels of MHC molecules and costimulatory molecules. 10 Moreover, these cloned DCs can present exogenous antigens on both MHC class I and II molecules.
In this study, the DC-V cell was transfected with pSCA1 construct encoding E7, BCL-xL, E7/BCL-xL, E7/ mt BCL-xL, or no insert. pcDNA3, a vector that does not induce cell death, was used as a negative control. As shown in Figure 1a , DC-V cells transfected with pSCA1 encoding either BCL-xL or E7/BCL-xL DNA delayed the death of DCs compared to DC-V cells transfected with pSCA1 encoding either E7 or no insert. All of the DC-V cells transfected with various pSCA1 vectors eventually led to cell death on day 6 after transfection. As a control, DC-V cells transfected with pcDNA3 vector did not lead to significant cell death 6 days after DNA transfection. These data demonstrated that the addition of BCL-xL gene to the pSCA1 DNA vector results in significant delay of cell death caused by the suicidal DNA vector.
To confirm whether the delay of cell death caused by pSCA1-E7/BCL-xL suicidal DNA vaccine was due to the antiapoptosis property of BCL-xL, we studied a BCL-xL mutant (mt BCL-xL) that lacks antiapoptotic function. As shown in Figure 1a , there is no significant difference in the percent of PI-positive cells at day 1 in the DC-V cells transfected with the various pSCA1 DNA constructs. However, at day 4 after transfection ( Figure 1b) , we observed that the percent of PI-positive cells in DC-V cells transfected with pSCA1 encoding E7/mt BCL-xL (91%), or no insert (90%) was significantly higher than DC-V cells transfected with pSCA1-E7/BCL-xL (34%). These results confirmed that the mutation in BCL-xL led to abrogation of the antiapoptotic function of BCL-xL.
The addition of BCL-xL to E7 in the pSCA1 vector significantly enhances E7-specific CD8 þ T-cellmediated immune responses in vaccinated mice
We hypothesized that the delay of suicidal DNA-induced cell death due to BCL-xL may enhance the priming BCL-xL enhances suicidal DNA vaccine potency TW Kim et al of antigen-specific T-cell-mediated immune responses when administered intradermally via gene gun. To assess the quantity of E7-specific IFN-g-secreting CD8 þ T-cell precursors generated by vaccination with the various pSCA1 DNA constructs, we performed intracellular cytokine staining followed by flow cytometry analysis. As shown in Figure 2a and b, C57BL/6 mice vaccinated with pSCA1-E7/BCL-xL generated the highest number of E7-specific IFN-g-secreting CD8
þ T-cell precursors (241.7712.7/3 Â 10 5 splenocytes) among the vaccinated groups with more than a 50-fold increase compared to mice vaccinated with pSCA1-E7 (4.071.0/ 3 Â 10 5 splenocytes) (Po0.01). Our results also indicated that the E7 antigen was required for the observed enhancement of E7-specific CD8 þ T-cell immune responses since pSCA1-BCL-xL did not enhance the number of E7-specific CD8 þ T cells (2.770.6/3 Â 10 5 splenocytes). These data indicate that the addition of BCL-xL to E7 in a suicidal DNA vaccine significantly enhances E7-specific CD8 þ T-cell-mediated immune responses in vaccinated mice.
The antiapoptotic function of BCL-xL is important for the enhancement of antigen-specific CD8 þ T-cell responses generated by pSCA1-E7/BCL-xL suicidal DNA vaccine
To confirm whether the observed enhancement of E7-specific CD8 þ T-cell response generated by pSCA1-E7/ BCL-xL suicidal DNA vaccine was due to the antiapoptosis property of BCL-xL, we studied a BCL-xL mutant (mt BCL-xL) that lacks antiapoptotic function. We compared the number of E7-specific IFN-g-secreting CD8
þ T-cell precursors in mice vaccinated with pSCA1-E7/BCL-xL or pSCA1-E7/mtBCL-xL. As shown in Figure 2a and b, while vaccination with pSCA1-E7/ BCL-xL suicidal DNA led to a high number of E7-specific IFN-g-secreting CD8 þ T-cell precursors (251.4712.7/3 Â 10 5 splenocytes), vaccination with pSCA1-E7/mt BCL-xL resulted in a significantly lower number of E7-specific IFN-g-secreting CD8 þ T-cell precursors (42.577.2/3 Â 10 5 splenocytes; Po0.001, analysis of variance (ANOVA)). Our results suggest that the antiapoptotic function of BCL-xL is important for the observed enhancement of the E7-specific CD8 þ T-cell immune response generated by the pSCA1-E7/BCL-xL DNA vaccine.
The addition of BCL-xL to E7 in the pSCA1 vector significantly enhances E7-specific antitumor effects in vaccinated mice
To determine if the observed enhancement in E7-specific CD8 þ T-cell-mediated immunity leads to a significant E7-specific antitumor effect, we performed an in vivo tumor protection experiment using a previously described E7-expressing tumor model, TC-1. 11 As shown in Figure 3a , 100% of C57BL/6 mice receiving the pSCA1-E7/BCL-xL suicidal DNA vaccine remained tumor-free 42 days after TC-1 challenge. In contrast, all of the mice receiving pSCA1 (no insert), pSCA1-BCL-xL, or pSCA1-E7 suicidal DNA developed tumors by day 10 after tumor challenge. These results indicated that the linkage of BCL-xL gene to E7 gene in a suicidal DNA vaccine significantly enhanced E7-specific antitumor effects in vaccinated mice.
To determine the subset of lymphocytes that is important for the antitumor effects generated by vaccination with pSCA1-E7/BCL-xL suicidal DNA, we performed an in vivo antibody depletion experiment. As shown in Figure 3b , all of the mice depleted of CD8 þ Figure 2 Intracellular cytokine staining followed by flow cytometry analysis to determine the number of E7-specific IFN-g-secreting CD8
þ T cells. Mice (three per group) were immunized with pSCA1 encoding BCL-xL, E7, E7/BCL-xL, or E7/mt BCL-xL. Mice vaccinated with pSCA1 (no insert) were used as a negative control. Splenocytes from vaccinated mice were harvested 7 days after a booster vaccination, cultured in vitro with MHC class I-restricted E7(aa 49-57) peptide overnight, and stained for both CD8 and intracellular IFN-g. þ T cells are important for the antitumor effect generated by the pSCA1-E7/BCL-xL suicidal DNA vaccine.
We also performed an in vivo tumor treatment experiment using a hematogenous spread pulmonary tumor model. 12 As shown in Figure 3c , mice immunized with pSCA1-E7/BCL-xL suicidal DNA vaccine exhibited the fewest numbers of pulmonary tumor nodules (0.270.4, Pp0.001, one-way ANOVA) compared to mice vaccinated with pSCA1 (no insert) (51.275.6), pSCA1-BCL-xL (52.677.0), or pSCA1-E7 (36.8714.3). Our results are consistent with a study by Pirtskhalaishvili et al, 13 who demonstrated that treatment of prostate cancer-bearing mice with BCL-xL-transduced DC resulted in significant inhibition of tumor growth compared to treatment with nontransduced DC. Taken together, these results indicate that vaccination with pSCA1-E7/BCL-xL suicidal DNA vaccine leads to potent protective and therapeutic effects against E7-expressing TC-1 tumor cells.
Discussion
We selected the BCL-xL protein as the antiapoptotic molecule for our studies because BCL-xL is considered to be one of the most potent antiapoptotic proteins. We have recently tested a variety of antiapoptotic factors for their ability to enhance DC survival and E7-specific CD8 þ T-cell immune responses when co-administered with E7 DNA, including BCL-xL 9,14 and BCL-2, 15, 16 members of the BCL-2 family of proteins; X-linked inhibitor of apoptosis protein (XIAP); 17 and dominantnegative (dn) mutants of caspases such as dn caspase-9 18 and dn caspase-8, 19 which have a mutation in the enzyme active site and serve as inhibitors of apoptosis. Our recent data on these apoptosis inhibitors indicated that BCL-xL demonstrated the greatest enhancement in antigen-specific immune responses and antitumor effects. 20 BCL-xL, like BCL-2, has been shown to localize to outer mitochondrial membranes and prevent release of proapoptotic factors from mitochondria, such as cytochrome c 21 and Smac/DIABLO, [22] [23] [24] by a mechanism that is not yet well understood. In addition, BCL-xL may inhibit apoptosis through a mitochondria-independent pathway. 25 Thus, BCL-xL may inhibit apoptosis at multiple points along the programmed cell death pathway, which explains why it is one of the most potent antiapoptotic factors. We therefore chose the BCL-xL molecule for our studies.
While our results suggest that the antiapoptotic function of the BCL-xL molecules is important for the observed enhancement of antigen-specific CD8
þ T-cell immune responses in pSCA1-E7/BCL-xL-vaccinated mice, there may be other explanations for observed enhancement of T-cell activation. For example, BCL-2 family proteins have been suggested to alter the differentiation status of cells, raising the possibility that DCs transfected with suicidal DNA encoding chimeric E7/BCL-xL molecule may lead to phenotypic changes of the transfected DCs, such as in the expression of MHC class I, MHC class II, or co-stimulatory molecules (B7-1, B7-2, and others). However, we did not observe changes in these molecules in DC-V cells transfected with the various pSCA-1 constructs (data not shown). Alternatively, the linkage of BCL-xL to E7 may influence the antigenic processing of E7 in suicidal DNA-transfected cells. Indeed, we have observed a slight increase of E7-specific CD8
þ T-cell precursors in mice vaccinated with pSCA1-E7/mt BCL-xL compared to mice vaccinated with pSCA1-E7 (Figure 2 ). Thus, it will be important to determine if there are multiple aspects of the BCL-xL molecule that can contribute to the observed enhancement of antigen-specific CD8
þ T-cell immune responses in the future.
The use of suicidal DNA vectors not only significantly alleviates the safety concerns related to DNA vaccines, such as integration, it also alleviates the concern of employment of oncogenic proteins such as the HPV-16 E7 antigen and the BCL-xL protein. One strategy to further improve safety is to use molecules that have antiapoptotic function with a reduced concern for oncogenicity, such as TRANCE, 26 CD40 ligand, 27 IL-12, 28 IL-15, 29 and serine protease inhibitor 6. 30 Among these molecules, CD40 ligand, 31 IL-12, 32 and IL-15 33 have been tested for their ability to enhance conventional naked DNA vaccine potency. Thus, it would be interest- BCL-xL enhances suicidal DNA vaccine potency TW Kim et al ing to evaluate the role these apoptosis inhibitors play in enhancing the antigen-specific immune responses to suicidal DNA vaccines.
While it is likely that directly transfected antigenexpressing APCs are mainly responsible for the observed E7-specific CD8 þ T-cell response to vaccination with suicide DNA encoding BCL-xL linked to E7, we cannot assume that all antigen-specific CD8 þ T cells are generated via this mechanism. It is possible that delivery of antigen to non-APCs and subsequent priming of T cells via a cross-priming mechanism 34 may also contribute to the generation of E7-specific CD8 þ T cells. The transfection of the DNA into non-APCs, such as keratinocytes, may eventually lead to the release of encoded antigen for uptake by APCs, such as DCs, which subsequently present antigen to naïve T cells. Thus, the observed enhancement of the E7-specific CD8 þ T-cell response generated by suicidal DNA encoding chimeric BCL-xL/E7 may be a result of multiple antigen presentation mechanisms.
In summary, the results of this study demonstrate that the use of the pSCA1-E7/BCL-xL suicidal DNA vaccine may alleviate the concerns of integration and transformation related to conventional DNA vaccines while generating strong E7-specific CD8 þ T-cell immune responses and antigen-specific antitumor effects. The promising results of this study encourage the application of this strategy to target other cancers or infectious diseases with known antigens.
Materials and methods

Plasmid DNA constructs
The generation of pcDNA3-E7 has been described previously.
8 pSG5 plasmids encoding BCL-xL 9 and mt 7 (mt BCL-xL) 9 in which aa 135-137 (NWG) in the BH1 domain were changed to AIL were described previously. For generation of pcDNA3-BCL-xL, BCL-xL was cut from pSG5-BCL-xL by BglII and was cloned into the unique BamHI cloning sites of the pcDNA3.1(À) expression vector (Invitrogen, Carlsbad, CA, USA). For generation of pcDNA3-mt BCL-xL, mt BCL-xL was cut from pSG5-mt BCL-xL by BglII and was cloned into the unique BamHI cloning sites of the pcDNA3.1(À) expression vector. For the generation of E7/BLC-xL chimera (pcDNA-E7/BCL-xL), BCL-xL was cut from pSG5-BCLxL by BglII and was cloned into the unique BamHI cloning sites of the pcDNA3-E7. For the generation of E7/mt BLC-xL chimera (pcDNA-mt E7/BCL-xL), mt BCL-xL was cut from pSG5-mt BCL-xL by BglII and was cloned into the unique BamHI cloning sites of the pcDNA3-E7. pSCA1 vector was a generous gift from Dr Rod Bremner at the University of Toronto. This pSCA1 vector contains human cytomegalovirus immediate-early gene (HCMV IE) promoter upstream of the Semliki Forest virus replicon. The subgenomic promoter is located after the Semliki Forest virus replicon, upstream of a multiple cloning site for the insertion of genes of interest. pSCA1-E7 was reported previously. 7 For the generation of pSCA1-BCL-xL, pSCA1-mt BCL-xL, pSCA1-E7/BCL-xL, and pSCA1-E7/mt BCL-xL, fragments of BCL-xL, mt BCL-xL, E7/BCL-xL, or E7/mt BCL-xL were cut from pcDNA3 vectors by BamHI-PmeI and cloned into BamHI-SmaI sites of pSCA1, respectively. The accuracy of these constructs was confirmed by DNA sequencing. The DNA was amplified in Escherichia coli DH5a and purified as described previously. 8 Mice and murine tumor cell line Female C57BL/6 mice (6-to 8-week-old) were purchased from the National Cancer Institute (Frederick, Maryland, USA) and stored in the oncology animal facility of the Johns Hopkins Hospital (Baltimore, MD, USA). All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
The production and maintenance of TC-1 cells has been described previously. 11 In brief, HPV-16 E6, E7, and ras oncogene were used to transform primary C57BL/6 mice lung epithelial cells to generate TC-1.
Survival of dendritic cell line
The immortalized DC line was kindly provided by Dr Kenneth Rock (University of Massachusetts, Worcester, MA, USA). 10 Briefly, the immortalized DC line was generated by transducing granulocyte-macrophage CSF into bone marrow cultures followed by transfection with myc and raf oncogenes. With continued passage, we have generated subclones of DCs (DC-V) that are easily transfected using Lipofectamine 2000 (Life Technologies, Rockville, MD, USA). DC-V was co-transfected with 2 mg of pcDNA3-GFP mixed with 2 mg of pSCA1 encoding BCL-xL, E7, E7/BCL-xL, mt BCL-xL, E7/mt BCL-xL, or no insert after the formation of Lipofectamine 2000/ DNA complexes. pcDNA3 (no insert) mixed with pcDNA3-GFP was used as a negative control. Detection of dead cells was performed using PI from BD Bioscience, San Diego, CA, USA according to vendor's protocol. The percent of cell death was analyzed using flow cytometry analysis by gating GFP þ cells, which represented the transfected cells. Data are expressed as percent of DC-V cell deaths.
DNA vaccination
DNA-coated gold particles were prepared according to a previously described protocol. 8 DNA-coated gold particles (1 mg DNA/bullet) were delivered to the shaved abdominal region of mice using a helium-driven gene gun (BioRad, Hercules, CA, USA) with a discharge pressure of 400 p.s.i. C57BL/6 mice were immunized with 2 mg of the pSCA1 encoding BCL-xL, E7, E7/BCLxL, E7/mt BCL-xL, or no insert. The mice received a booster with the same regimen 1 week later.
Intracellular cytokine staining and flow cytometry analysis
Splenocytes were harvested from mice 1 week after the last vaccination. Prior to intracellular cytokine staining, 3 Â 10 5 pooled splenocytes from each vaccination group were incubated for 16 h with 1 mg/ml of E7 peptide (RAHYNIVTF) containing an MHC class I epitope for detecting antigen-specific CD8 þ T-cell precursors. Intracellular IFN-g staining and flow cytometry analysis were performed as described previously. 8 Analysis was performed on a Becton-Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA).
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In vivo tumor protection experiment
For the tumor protection experiment, C57BL/6 mice (five per group) were vaccinated via gene gun with 2 mg of pSCA1 (no insert), pSCA1-BCL-xL, pSCA1-E7, or pSCA1-E7/BCL-xL via gene gun. After 1 week, mice were boosted with the same regimen as the first vaccination. At 1 week after the last vaccination, mice were subcutaneously challenged with 5 Â l0 4 cells/ mouse TC-1 tumor cells in the right leg and then monitored twice a week.
In vivo tumor treatment experiment
For the tumor treatment experiment, mice were challenged with 1 Â l0 4 TC-1 tumor cells/mouse in the tail vein to simulate hematogenous spread of tumors. 35 At 3 days after challenge with TC-1 tumor cells, mice were administered 2 mg of pSCA1 (no insert), pSCA1-BCL-xL, pSCA1-E7, or pSCA1-E7/BCL-xL via gene gun. After 1 week, these mice were boosted with the same regimen as the first vaccination. Mice were killed and lungs were explanted on day 21. The pulmonary nodules in each mouse were evaluated and counted by experimenters blinded to sample identity.
In vivo antibody depletion experiment
In vivo antibody depletions have been described previously. 11 Briefly, C57BL/6 mice (five per group) were vaccinated with pSCA1-E7/BCL-xL via gene gun, boosted 1 week later with the same dose, and challenged with 5 Â l0 4 cells/mouse TC-1 tumor cells subcutaneously 1 week after the last vaccination. Depletions were started 1 week prior to tumor challenge. mAb GK1.5, mAb 2.43, and mAb PK136 (Harlan, Indianapolis, IA, USA) were used for CD4 depletion, CD8 depletion, and NK1.1 depletion, respectively. Depletion was terminated on day 90 after tumor challenge.
Statistical analysis
All data expressed as means7s.e.m. are representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis and tumor treatment experiments were analyzed by ANOVA. Comparisons between individual data points were made using a Student's t-test. Kaplan-Meier survival curves for tumor protection experiments and in vivo antibody depletion experiments were applied; for differences between curves, P-values were calculated using the log-rank test. Po0.05 was considered significant.
